Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Nasal_Spray
Hikma is looking to bring anaphylaxis treatment epinephrine and the opioid overdose drug naloxone to the US market as unit-dose nasal sprays • Source: Shutterstock

Hikma Pharmaceuticals has signed an agreement to acquire for $17.0m pipeline epinephrine and naloxone nasal sprays and a complementary manufacturing platform from Insys Therapeutics, which recently filed for bankruptcy. Both the epinephrine and naloxone sprays are intended for approval through the US Food and Drug Administration’s hybrid 505(b)(2) regulatory pathway.

Speaking exclusively to Generics Bulletin immediately after announcing the deal, Hikma’s CEO Siggi Olafsson described the Insys assets acquisition as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

Neuraxpharm Enters Japanese Market 1

 
• By David Wallace

Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

Hyloris Sets Out Plans To Expand Its Pipeline

 
• By Akriti Seth

After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

Awards Offers Two Weeks Of Online Networking

 
• By David Wallace

From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

Hyloris And Purna Strike Value-Added Development Deal

 
• By David Wallace

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.